Literature DB >> 30314420

Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen.

Leonhard A Bakker1,2, Carin D Schröder2,3, Lauriane A Spreij2, Marianne Verhaegen4, Joke De Vocht4, Philip Van Damme4,5,6, Jan H Veldink1, Johanna M A Visser-Meily2,3, Leonard H van den Berg1, Tanja C W Nijboer2,3,7, Michael A van Es1.   

Abstract

BACKGROUND: The Edinburgh cognitive and behavioral ALS screen (ECAS) was developed specifically to detect cognitive and behavioral changes in patients with amyotrophic lateral sclerosis (ALS). Differences with regard to normative data of different (language) versions of neuropsychological tests such as the ECAS exist.
OBJECTIVE: To derive norms for the Dutch version of the ECAS.
METHODS: Normative data were derived from a large sample of 690 control subjects and cognitive profiles were compared between a matched sample of 428 patients with ALS and 428 control subjects.
RESULTS: Age, level of education, and sex were significantly associated with performance on the ECAS in the normative sample. ECAS data were not normally distributed and therefore normative data were expressed as percentile ranks. The comparison of ECAS scores between patients and control subjects demonstrated that patients obtained significantly lower scores for language, executive function, verbal fluency, and memory, which is in line with the established cognitive profile of ALS.
CONCLUSION: For an accurate interpretation of ECAS results, it is important to derive normative data in large samples with nonparametric methods. The present normative data provide healthcare professionals with an accurate estimate of how common or uncommon patients' ECAS scores are and provide a useful supplement to existing cut-off scores.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Edinburgh cognitive and behavioral ALS screen; cognitive dysfunction; normative data

Mesh:

Year:  2018        PMID: 30314420     DOI: 10.1080/21678421.2018.1522352

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  3 in total

1.  Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches.

Authors:  Corey T McMillan; Joanne Wuu; Katya Rascovsky; Stephanie Cosentino; Murray Grossman; Lauren Elman; Colin Quinn; Luis Rosario; Jessica H Stark; Volkan Granit; Hannah Briemberg; Sneha Chenji; Annie Dionne; Angela Genge; Wendy Johnston; Lawrence Korngut; Christen Shoesmith; Lorne Zinman; Sanjay Kalra; Michael Benatar
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2022-03-07       Impact factor: 3.528

2.  Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion.

Authors:  Joke De Vocht; Jeroen Blommaert; Martijn Devrome; Ahmed Radwan; Donatienne Van Weehaeghe; Maxim De Schaepdryver; Jenny Ceccarini; Ahmadreza Rezaei; Georg Schramm; June van Aalst; Adriano Chiò; Marco Pagani; Daphne Stam; Hilde Van Esch; Nikita Lamaire; Marianne Verhaegen; Nathalie Mertens; Koen Poesen; Leonard H van den Berg; Michael A van Es; Rik Vandenberghe; Mathieu Vandenbulcke; Jan Van den Stock; Michel Koole; Patrick Dupont; Koen Van Laere; Philip Van Damme
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

3.  Multimodal longitudinal study of structural brain involvement in amyotrophic lateral sclerosis.

Authors:  Hannelore K van der Burgh; Henk-Jan Westeneng; Renée Walhout; Kevin van Veenhuijzen; Harold H G Tan; Jil M Meier; Leonhard A Bakker; Jeroen Hendrikse; Michael A van Es; Jan H Veldink; Martijn P van den Heuvel; Leonard H van den Berg
Journal:  Neurology       Date:  2020-05-15       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.